| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Koichi Fujisawa, Toshihiko Matsumoto, Isao Hidaka, Yoshio Marumoto, Tsuyoshi Ishikawa, Naoki Yamamoto, Yutaka Suehiro, Taro Takami and Isao Sakaida |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Japan Society for the Promotion of Science, KIBAN-B |
05287 |
|
| Corresponding Author |
Takahiro Yamasaki, MD, PhD, Professor, Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube 755-8505, Japan. t.yama@yamaguchi-u.ac.jp |
| Key Words |
Treatment strategy; Hepatic arterial infusion chemotherapy; Sorafenib; Hepatocellular carcinoma |
| Core Tip |
In Japan, sorafenib and hepatic arterial infusion chemotherapy (HAIC) are described as treatment options for hepatocellular carcinoma (HCC). Although no randomized controlled trials have compared these treatments, retrospective analyses have shown similar survival between them. Sorafenib is generally used for Child-Pugh A, while HAIC is indicated for Child-Pugh A or B. Compared to sorafenib, HAIC shows better responses in cases exhibiting macroscopic vascular invasion. After reviewing treatment strategies for advanced HCC, we recommended sorafenib as first-line treatment for cases without macroscopic vascular invasion or Child-Pugh A, and HAIC for those with macroscopic vascular invasion or Child-Pugh A or B. |
| Publish Date |
2018-09-27 09:38 |
| Citation |
Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 |
| URL |
http://www.wjgnet.com/1948-5182/full/v10/i9/571.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v10.i9.571 |
